Evaluation of Anti-Zika Virus Activities of Broad-Spectrum Antivirals and NIH Clinical Collection Compounds Using a Cell-Based, High-Throughput Screen Assay
February 2017
in “
Antiviral research
”
TLDR Researchers found several compounds that could potentially treat Zika virus.
The study developed a cytopathic effect (CPE)-based, high-throughput screening (HTS) assay to evaluate anti-Zika virus (ZIKV) activities of broad-spectrum antivirals and compounds from the NIH Clinical Collection. Using Vero 76 cells, the assay tested the antiviral potency of several compounds against two ZIKV strains, MR766 and PRVABC59. The results indicated that pyrimidine synthesis inhibitors could be potential therapeutics for ZIKV. This assay provided a reliable method for identifying multiple chemotypes of ZIKV inhibitors, addressing the urgent need for effective anti-ZIKV therapeutics.
